MMP-2 as a putative biomarker for carcinomatosis in gastric cancer

Sewon Noh, Jae Joon Jung, Minkyu Jung, Tae Soo Kim, Chan Hee Park, Seung Joon Lim, Hei Cheul Jeung, Hyuncheol Chung, SunYoung Rha

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background/Aims: We evaluated matrix metalloproteinase (MMP)-2 and -9 as novel biomarkers in the body fluid of advanced gastric cancer with peritoneal and pleural metastasis. Methodology: MMPs activity from zymography was quantified with ELISA to determine the cut-off expression levels of MMPs. The expression of MMPs in patient samples were evaluated with ELISA and compared with clinical parameters. Ascitic CEA (aCEA) and pleural CEA (pCEA) were measured by chemiluminescent enzyme immunoassay. Results: MMP-2 and -9 cut-off levels were 8.6ng/mL and 0.14ng/mL, respectively. Ascitic fluid cytology of 93 patients revealed a positivity of 55.9% while for MMP-2 it was 93.3%, for MMP-9 35.2% and for aCEA 86.7%. Combining biomarkers, the positivity increased to 99.1% in patients with MMP-2 and aCEA expression. We found a negative correlation between MMP-2 expression and survival when a new prognostic cut-off of 22.6ng/mL was used. Patients with high MMP-2 expression (≥22.6ng/mL) had a median survival of 45 days and those with low MMP-2 expression (<22.6ng/mL) had a median survival of 69 days (p<0.01). Conclusions: These results suggest that MMPs could be used as diagnostic markers in body fluid and MMP-2 might be a prognostic marker in ascites of advanced gastric patients with disseminated metastasis.

Original languageEnglish
Pages (from-to)2015-2019
Number of pages5
JournalHepato-Gastroenterology
Volume58
Issue number112
DOIs
Publication statusPublished - 2011 Nov 1

Fingerprint

Matrix Metalloproteinase 2
Stomach Neoplasms
Biomarkers
Carcinoma
Matrix Metalloproteinases
Matrix Metalloproteinase 9
Body Fluids
Survival
Enzyme-Linked Immunosorbent Assay
Neoplasm Metastasis
Ascitic Fluid
Immunoenzyme Techniques
Ascites
Cell Biology
Stomach

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Noh, S., Jung, J. J., Jung, M., Kim, T. S., Park, C. H., Lim, S. J., ... Rha, S. (2011). MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Hepato-Gastroenterology, 58(112), 2015-2019. https://doi.org/10.5754/hge11209
Noh, Sewon ; Jung, Jae Joon ; Jung, Minkyu ; Kim, Tae Soo ; Park, Chan Hee ; Lim, Seung Joon ; Jeung, Hei Cheul ; Chung, Hyuncheol ; Rha, SunYoung. / MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. In: Hepato-Gastroenterology. 2011 ; Vol. 58, No. 112. pp. 2015-2019.
@article{c88ed889a06045cc9da58351873c2c22,
title = "MMP-2 as a putative biomarker for carcinomatosis in gastric cancer",
abstract = "Background/Aims: We evaluated matrix metalloproteinase (MMP)-2 and -9 as novel biomarkers in the body fluid of advanced gastric cancer with peritoneal and pleural metastasis. Methodology: MMPs activity from zymography was quantified with ELISA to determine the cut-off expression levels of MMPs. The expression of MMPs in patient samples were evaluated with ELISA and compared with clinical parameters. Ascitic CEA (aCEA) and pleural CEA (pCEA) were measured by chemiluminescent enzyme immunoassay. Results: MMP-2 and -9 cut-off levels were 8.6ng/mL and 0.14ng/mL, respectively. Ascitic fluid cytology of 93 patients revealed a positivity of 55.9{\%} while for MMP-2 it was 93.3{\%}, for MMP-9 35.2{\%} and for aCEA 86.7{\%}. Combining biomarkers, the positivity increased to 99.1{\%} in patients with MMP-2 and aCEA expression. We found a negative correlation between MMP-2 expression and survival when a new prognostic cut-off of 22.6ng/mL was used. Patients with high MMP-2 expression (≥22.6ng/mL) had a median survival of 45 days and those with low MMP-2 expression (<22.6ng/mL) had a median survival of 69 days (p<0.01). Conclusions: These results suggest that MMPs could be used as diagnostic markers in body fluid and MMP-2 might be a prognostic marker in ascites of advanced gastric patients with disseminated metastasis.",
author = "Sewon Noh and Jung, {Jae Joon} and Minkyu Jung and Kim, {Tae Soo} and Park, {Chan Hee} and Lim, {Seung Joon} and Jeung, {Hei Cheul} and Hyuncheol Chung and SunYoung Rha",
year = "2011",
month = "11",
day = "1",
doi = "10.5754/hge11209",
language = "English",
volume = "58",
pages = "2015--2019",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "112",

}

Noh, S, Jung, JJ, Jung, M, Kim, TS, Park, CH, Lim, SJ, Jeung, HC, Chung, H & Rha, S 2011, 'MMP-2 as a putative biomarker for carcinomatosis in gastric cancer', Hepato-Gastroenterology, vol. 58, no. 112, pp. 2015-2019. https://doi.org/10.5754/hge11209

MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. / Noh, Sewon; Jung, Jae Joon; Jung, Minkyu; Kim, Tae Soo; Park, Chan Hee; Lim, Seung Joon; Jeung, Hei Cheul; Chung, Hyuncheol; Rha, SunYoung.

In: Hepato-Gastroenterology, Vol. 58, No. 112, 01.11.2011, p. 2015-2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MMP-2 as a putative biomarker for carcinomatosis in gastric cancer

AU - Noh, Sewon

AU - Jung, Jae Joon

AU - Jung, Minkyu

AU - Kim, Tae Soo

AU - Park, Chan Hee

AU - Lim, Seung Joon

AU - Jeung, Hei Cheul

AU - Chung, Hyuncheol

AU - Rha, SunYoung

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Background/Aims: We evaluated matrix metalloproteinase (MMP)-2 and -9 as novel biomarkers in the body fluid of advanced gastric cancer with peritoneal and pleural metastasis. Methodology: MMPs activity from zymography was quantified with ELISA to determine the cut-off expression levels of MMPs. The expression of MMPs in patient samples were evaluated with ELISA and compared with clinical parameters. Ascitic CEA (aCEA) and pleural CEA (pCEA) were measured by chemiluminescent enzyme immunoassay. Results: MMP-2 and -9 cut-off levels were 8.6ng/mL and 0.14ng/mL, respectively. Ascitic fluid cytology of 93 patients revealed a positivity of 55.9% while for MMP-2 it was 93.3%, for MMP-9 35.2% and for aCEA 86.7%. Combining biomarkers, the positivity increased to 99.1% in patients with MMP-2 and aCEA expression. We found a negative correlation between MMP-2 expression and survival when a new prognostic cut-off of 22.6ng/mL was used. Patients with high MMP-2 expression (≥22.6ng/mL) had a median survival of 45 days and those with low MMP-2 expression (<22.6ng/mL) had a median survival of 69 days (p<0.01). Conclusions: These results suggest that MMPs could be used as diagnostic markers in body fluid and MMP-2 might be a prognostic marker in ascites of advanced gastric patients with disseminated metastasis.

AB - Background/Aims: We evaluated matrix metalloproteinase (MMP)-2 and -9 as novel biomarkers in the body fluid of advanced gastric cancer with peritoneal and pleural metastasis. Methodology: MMPs activity from zymography was quantified with ELISA to determine the cut-off expression levels of MMPs. The expression of MMPs in patient samples were evaluated with ELISA and compared with clinical parameters. Ascitic CEA (aCEA) and pleural CEA (pCEA) were measured by chemiluminescent enzyme immunoassay. Results: MMP-2 and -9 cut-off levels were 8.6ng/mL and 0.14ng/mL, respectively. Ascitic fluid cytology of 93 patients revealed a positivity of 55.9% while for MMP-2 it was 93.3%, for MMP-9 35.2% and for aCEA 86.7%. Combining biomarkers, the positivity increased to 99.1% in patients with MMP-2 and aCEA expression. We found a negative correlation between MMP-2 expression and survival when a new prognostic cut-off of 22.6ng/mL was used. Patients with high MMP-2 expression (≥22.6ng/mL) had a median survival of 45 days and those with low MMP-2 expression (<22.6ng/mL) had a median survival of 69 days (p<0.01). Conclusions: These results suggest that MMPs could be used as diagnostic markers in body fluid and MMP-2 might be a prognostic marker in ascites of advanced gastric patients with disseminated metastasis.

UR - http://www.scopus.com/inward/record.url?scp=84863232116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863232116&partnerID=8YFLogxK

U2 - 10.5754/hge11209

DO - 10.5754/hge11209

M3 - Article

VL - 58

SP - 2015

EP - 2019

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 112

ER -

Noh S, Jung JJ, Jung M, Kim TS, Park CH, Lim SJ et al. MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Hepato-Gastroenterology. 2011 Nov 1;58(112):2015-2019. https://doi.org/10.5754/hge11209